Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

NOA Lithium Strikes Critical Water: A Game-Changing Discovery for Rio Grande Project

Global Markets News

In the parched landscapes of Argentina's Lithium Triangle, water is as valuable as the lithium itself. NOA Lithium Brines Inc. (TSXV: NOAL) (OTCPK: NLIBF) has just announced a discovery that could dramatically accelerate the development timeline of its flagship Rio Grande Project—fresh water. The company revealed today that it has successfully located an on-site fresh water source within its 100%-owned Rio Grande Project boundaries, marking a pivotal milestone in the project's advancement toward production. Why This Water Discovery Matters For lithium brine projects, access to industrial water is a make-or-break factor. In the arid regions where lithium salars are typically found, securing water rights and sources can be challenging, expensive, and time-consuming. By discovering this resource on its own property, NOA has eliminated a significant hurdle in the development pathway. "This marks another significant milestone in the advancement of the Rio Grande Project," stated Gabriel Rubacha, NOA's Chief Executive Officer. "Not only have we discovered a fresh water source on-site and within our properties, but its location aligns perfectly with the area of highest lithium concentration and our preliminary assessment for locating a production facility and evaporation ponds." The strategic positioning of this water well, drilled to a depth of 190 meters in the northern section of the project, couldn't be more advantageous. It's situated close to the areas where NOA has identified the highest concentration of lithium and porosity to date—precisely where the company envisions developing future production facilities and evaporation ponds. A Series of Strategic Wins This water discovery adds to NOA's impressive streak of achievements over the past year. The company has methodically checked off critical boxes in its development roadmap: The water well represents one of three fresh water targets identified at Rio Grande, suggesting further potential for expanded water resources as development continues. Positioned in the Heart of the Lithium Triangle NOA's strategic position in Argentina's Lithium Triangle gives it proximity to some of the world's highest-grade, lowest-cost lithium operations. The company has assembled one of the largest lithium brine claim portfolios in the region not owned by a producing company, with over 140,000 hectares across three prospective salars: Rio Grande, Arizaro, and Salinas Grandes. This vast land package in Salta Province—widely recognized as one of Argentina's most mining-friendly jurisdictions—positions NOA alongside industry leaders like Arcadium, Lithium Argentina, Ganfeng, and Rio Tinto. Looking Forward: Accelerating Development With the PEA expected in Q3 2025, NOA is rapidly advancing toward a comprehensive economic evaluation of the Rio Grande Project. The current design contemplates an initial production capacity of approximately 20,000 metric tonnes per year of lithium carbonate equivalent, with scalability to double that capacity through modular expansion. The water discovery adds tangible value to this economic assessment by potentially reducing both capital and operating costs associated with water procurement and transport. As global lithium demand continues to surge, driven by electric vehicle adoption and energy storage requirements, NOA's steady advancement of its Rio Grande Project positions it as an emerging player in the lithium supply chain at precisely the right time. For investors watching the lithium space, NOA's methodical derisking of its flagship project and continued achievement of development milestones make it a compelling story to follow as it progresses toward its goal of becoming Argentina's next major lithium producer. ‎ Recent News Highlights from NOA Lithium: NOA Lithium Discovers Fresh Water at Rio Grande Project NOA Engages Hatch To Lead Preliminary Economic Assessment For Its Rio Grande Project NOA Lithium Advances Towards 2025 Water Exploration at Rio Grande Project Read more about other lithium stocks: NASDAQ: PWM | OTC: LTMCF | NYSE: ALB | NYSE: LAC | OTCQB:NRVTF * Legal Disclaimer & Disclosure - Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from NOA Lithium Brines Inc. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available here redditwire.com/terms or in NOA's disclosure's THIS ARTICLE CONTAINS SPONSORED CONTENT PUBLISHED ON BEHALF OF NOA LITHIUM BRINES Contact Details ‎ media.globalmarkets@gmail.com

June 24, 2025 09:18 AM Eastern Daylight Time

News Release

DarioHealth's Platform Solves GLP-1's Biggest Problem, New Research Shows, While Trading at 1% of Hinge Health's $3 Billion Valuation

Global Markets News

DarioHealth Corp. (NASDAQ: DRIO), a digital health innovator in the chronic condition management space, just unveiled significant research findings at the American Diabetes Association Scientific Sessions that could dramatically improve its position in the $100 billion weight loss market. The company's studies demonstrate sustainable outcomes for GLP-1 users even after discontinuing medication - addressing a critical challenge in the industry. The latest findings revealed dramatic improvements in GLP-1 users, with average blood glucose levels dropping from an estimated A1c of 9.0% to 6.7%. Most importantly, users who discontinued GLP-1 medication maintained stable outcomes with no significant weight or glucose rebound for at least six months, according to the company's research. The company's platform leverages artificial intelligence to deliver personalized interventions, with its AI predictive models achieving 89% accuracy in forecasting future glucose levels. These capabilities position DarioHealth to support the growing demand for effective GLP-1 management solutions. Valuation Gap Creates Opportunity With DRIO shares currently trading around $0.69 and a market cap of approximately $30 million, the company appears dramatically undervalued compared to digital health peers. Hinge Health (NYSE: HNGE), which focuses primarily on musculoskeletal care, recently completed its IPO in May 2025 and now trades with a market cap of over $3 billion. This valuation disparity highlights the potential upside for DarioHealth investors. Unlike Hinge Health's focus on musculoskeletal care, DarioHealth offers a multi-condition platform addressing diabetes, hypertension, weight management, and behavioral health. This broader approach provides more comprehensive value to health plans and employers seeking to consolidate digital health vendors. DarioHealth has made strategic moves to strengthen its market position: The company expanded its GLP-1 capabilities through a partnership with MediOrbis, adding prescribing capabilities to enhance its weight management solution It's targeting both employer markets and direct-to-consumer channels The company has built its client base to 97 organizations with a reported 90%+ renewal rate The latest research validates DarioHealth's approach to sustainable weight management. With 44% of large employers now covering obesity drugs according to a Mercer survey, the demand for supportive digital health tools continues to grow. The Financial Picture DarioHealth has been making progress toward improved financial performance. In Q1 2025, the company reported revenue of $6.75 million, a 17% year-over-year increase, with gross margins of 57.5% (70.5% on a non-GAAP basis). Operating expenses decreased 35% compared to the previous year, as the company works toward its stated goal of operational cash flow breakeven by the end of 2025. The Bottom Line As GLP-1 medications continue to reshape weight management approaches, DarioHealth's platform offers a solution to maintain outcomes beyond medication use. The company's comprehensive condition management approach contrasts with more narrowly focused digital health providers like Hinge Health. For investors interested in the digital health sector, DarioHealth may represent an opportunity at current price levels, though it carries the execution risks typical of smaller healthcare technology companies. The significant valuation gap between DarioHealth's $30 million market cap and Hinge Health's $3 billion valuation highlights the potential upside if the company continues to execute on its strategy and build on its latest research findings. ‎ Recent News from Dario: Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings DarioHealth Reports First Quarter 2025 Financial and Operating Results Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025 DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives ‎ Important Legal Disclaimer & Disclosur e - Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from DarioHealth Corp. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. Contact Details ‎ media.globalmarkets@gmail.com

June 24, 2025 09:07 AM Eastern Daylight Time

Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Treatment For Basal Cell Carcinoma Could Upend The $15 Billion Market

Medicus Pharma Ltd (MDCX)

Skin cancer is the most common form of cancer in the United States, with more than 9,500 cases getting diagnosed every day. In fact, more people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. The most common form of skin cancer is basal cell carcinoma (BCC), which accounts for over 5 million cases of all skin cancers diagnosed in the U.S. each year. Currently, the standard treatment for most BCC patients is surgery, either standard excision or Mohs micrographic surgery, which has led to a significant unmet medical need for a non-surgical option. That is why Medicus Pharma Ltd. (NASDAQ:MDCX), a life sciences company focused on accelerating the clinical development programs of novel therapeutic assets, has been attracting investor attention with its revolutionary new treatment that is under development. A non-invasive novel approach Medicus, through its wholly owned subsidiary SkinJect Inc., is focused on commercializing a novel, non-invasive treatment for basal cell carcinoma using a patented dissolvable microneedle patch. The patch is thumb-sized, and what makes it particularly unique is its ability to deliver a chemotherapeutic agent (doxorubicin) to kill tumor cells on the skin and induce a memory immune response to prevent cancer recurrence. Microneedles are promising devices for painless drug delivery, which can improve the biological effect of drugs through adjustable drug release. This novel non-invasive regimen to treat skin cancer, especially BCC, therefore represents a potentially attractive alternative to surgery and current topical therapeutic options. So far, preliminary trial results have been quite promising. The company completed a Phase I study for SkinJect in March 2021 for participants with superficial and nodular BCC, which met its primary objective of safety and tolerability. In January 2024, a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study that began enrollment in August with 60 patients. According to Medicus, an interim analysis of the ongoing clinical study reveals that SKNJCT-003 is trending positively, with a proportion of subjects with complete clinical clearance of more than 60%. In April this year, the company announced that the Institutional Review Board (IRB) had approved an increase in the number of patients from 60 to 90, further highlighting the company’s progress towards validation. The company plans to submit the interim analysis to the FDA as part of a package seeking a Type C meeting with the regulator in Q2 2025 with the aim of seeking approval to fast-track the clinical development program. At the same time, the company has said that it will be expanding the phase 2 clinical study into additional sites in the US from the current nine sites as well as two clinical trial sites in Europe. In addition to that, Medicus has received the study may proceed approval from the UAE Department of Health to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC. The study is expected to randomize 36 patients in four sites in the UAE. It’s also important to note that the company hasn't limited SkinJect to treating humans only. Last year Medicus received a Minor Use in Major Species Designation (MUMS) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. MUMS is a designation that is comparable to orphan drug status for human medications. Earlier this month, the company revealed that it had submitted a comprehensive product development plan to treat external SCC under Investigational New Animal Drug, designed to seek concurrence of the FDA under MUMS designation. Significant revenue opportunity As mentioned earlier, the potential addressable market for SkinJect is quite significant. About 40–50% of Americans who live to age 65 will experience BCC or SCC at least once. And while still most prevalent in the older segments of the population, it is becoming ever more frequent in younger individuals. BCC procedures are projected to grow at 4% per annum, reaching 6 million procedures in 2030, representing a market size in excess of $15 billion annually, and Medicus is well positioned to capture a significant share of this market if SkinJect is approved due to a couple of reasons. For starters, it is a less painful, less invasive way to treat skin cancer and also lowers the likelihood of recurrence. Secondly, while Mohs surgery costs range between $2,000 and $15,000, the cost of three SkinJect microneedle patches is estimated at $1,000, illustrating the potential for significant cost savings for patients. Furthermore, SkinJect can be administered the same day as a diagnosis, while the average lead time for surgery in the US spans 2–8 months. Apart from that, the overall incidence of SCC in horses is 2-3%, and recent estimates of the US horse population range from 6.6 to 7.25 million horses. With only a handful of approved oncology drugs in the veterinary market, the company believes that developing a non-invasive treatment for equine SCC represents an untapped and unmet market opportunity potentially in the range of $250 million. Medicus has continued to show its commitment to unlocking more shareholder value with its recent announcement of a binding letter of intent to acquire Antev Ltd. for $75 million in a share exchange transaction. Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, as the first in-market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. Collectively, this represents an additional $6 billion in potential market opportunities for Medicus. Antev shareholders will receive an aggregate 19% equity stake in Medicus, plus $65 million in additional contingent payments tied to potential future FDA Phase 2 and New Drug Application approvals. The transaction is expected to close before the end of June. Takeaway Medicus recently announced the closing of its $7 million public offering, which will be used to fund its Phase 2 proof-of-concept clinical trial, further illustrating investor confidence in the company’s progress so far and future prospects. As such, investors searching for a unique opportunity in the cancer treatment space should consider taking a closer look at Medicus before it gains mainstream traction. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by MDCX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

June 24, 2025 07:00 AM Eastern Daylight Time

News Release

The $4.1 Trillion Healthcare Revolution: How DarioHealth Could Rewrite the Rules of Chronic Disease Management

Global Markets News

Imagine a world where managing multiple chronic conditions isn’t a nightmare of fragmented care, endless appointments, and mounting medical bills. This isn’t a futuristic fantasy, it’s the vision of DarioHealth Corp. (NASDAQ: DRIO)*, a digital health company that’s quietly building what could be the most comprehensive solution to America’s chronic disease crisis. The numbers are staggering. Chronic diseases consume a mind-boggling 90% of the $4.1 trillion U.S. healthcare budget, according to the CDC. Worse, 42% of Americans juggle multiple chronic conditions, with 12% managing five or more. It’s a system broken beyond repair, or so it seemed. Enter DarioHealth, a digital health innovator that’s reimagining healthcare from the ground up. Unlike traditional point solutions that tackle one condition at a time, this company has developed an AI-powered platform that simultaneously addresses diabetes, hypertension, weight management, musculoskeletal pain, and mental health. The company’s journey is as compelling as its technology. Born from years of user interaction data spanning 150,000 consumers, DarioHealth has built more than just an app, it’s created an intelligent ecosystem that learns and adapts to individual health journeys. Their AI-driven platform isn’t just tracking metrics; it’s predicting and preventing health complications before they escalate. But this isn’t just another tech pipe dream. The company’s approach is delivering real-world results that are turning heads across the healthcare industry. Imagine reducing hyperglycemic events by 58%, cutting anxiety symptoms by 59%, and delivering a 5x return on investment for healthcare payers. These aren’t marketing promises, they’re proven outcomes. The GLP-1 weight loss revolution provides a perfect window into DarioHealth’s strategic brilliance. With the weight loss medication market set to explode to $100 billion by 2030, the company has positioned itself as more than just a support platform. Through a strategic partnership with MediOrbis, they now offer integrated medication prescribing, solving the critical problem that sees 75% of patients discontinuing GLP-1 medications within a year. 2025 has been a breakthrough year. The company has added 14 new clients, bringing their total to 97 organizations. More importantly, over 80% of new contracts now cover multiple health conditions, a clear validation of their holistic approach. Major players like Blue Cross Blue Shield are taking notice, and the company’s client renewal rate sits at an impressive 90%. Financially, the story is equally compelling. First-quarter 2025 revenues hit $6.75 million, a 17% year-over-year growth. But the real magic is happening behind the scenes. The company is deploying AI to streamline operations, with a laser focus on reaching operational cash flow breakeven by the end of 2025 or early 2026. Recent industry comparisons, like the recent IPO of Omada Health (NASDAQ: OMDA) at much higher multiples, highlight the potential undervaluation of DarioHealth’s innovative platform. For investors tired of overhyped tech promises, DarioHealth may offer something different. Trading at around $0.69 with a market cap of ~$30 million, this could be the definition of a hidden gem. The company isn’t just building a product, it’s reimagining how chronic disease management could work in the digital age. Consider the market opportunity. With 129 million Americans suffering from at least one major chronic disease, and healthcare costs continuing to spiral, DarioHealth sits at the intersection of a massive market need and technological innovation. Recent analyst reports have even suggested the stock could reach $3, a potential 335% upside from current levels. This isn’t just another digital health play. This is a potential blueprint for the future of healthcare, personalized, integrated, and powered by intelligent technology. In a world where healthcare complexity continues to grow, DarioHealth represents a beacon of hope, promising not just management, but meaningful transformation of how we approach chronic health. ‎ ‎ Recent News Highlights from Dario DarioHealth Reports First Quarter 2025 Financial and Operating Results Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025 DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives - * Legal Disclaimer & Disclosure - Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from DarioHealth Corp. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. Contact Details ‎ media.globalmarkets@gmail.com

June 23, 2025 10:54 AM Eastern Daylight Time

Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)

Global Markets News

In a market where noise often overshadows substance, Nuvectis Pharma (NASDAQ:NVCT)* is delivering a signal that’s hard to ignore — sustained insider buying by one of the company’s most informed and sophisticated investors. On June 20, 2025, Charles Mosseri-Marlio, a well-known biotech investor and former pharmaceutical executive, filed a Form 4 disclosing the purchase of 33,442 additional shares of NVCT at $8.05 per share. The $270,000 transaction adds to his already significant position, which now totals just under 3 million shares through Emerald Hill Capital. This marks the third major insider buy by Mosseri-Marlio in 2025 alone — with previous purchases in February and May at lower price points. The pattern is clear: this is not opportunistic trading, it’s strategic accumulation. What makes this even more notable is Mosseri-Marlio’s background. He previously held a leadership role at Flamel Technologies (now Avadel Pharmaceuticals), where he helped secure development deals with top-tier partners like Pfizer and GlaxoSmithKline. He’s not only familiar with drug pipelines — he’s built them. Combined with a track record in institutional asset management, his buying carries more weight than your average insider move. He’s not chasing momentum — he’s betting on execution. And there’s plenty in the Nuvectis pipeline to justify that bet. The company is currently advancing two first-in-class oncology candidates — NXP800 and NXP900 — both of which are in clinical trials targeting cancers with high unmet need. NXP800 is in Phase 1b development for ARID1a-mutated, platinum-resistant ovarian cancer — a devastating subtype with few effective treatments. The drug has already earned Fast Track and Orphan Drug designations from the FDA, streamlining its development and signaling strong regulatory support. Data from this trial is expected later this year, and could be a key near-term catalyst. NXP900, meanwhile, is designed to address drug resistance in advanced cancers, including non-small cell lung cancer. By inhibiting SRC and YES1 kinases, NXP900 targets the very mechanisms that allow tumors to escape the effects of EGFR and ALK inhibitors — two of the most common first-line treatments in NSCLC. After completing its Phase 1a study, the company is now preparing to launch combination trials that could demonstrate its potential to restore drug sensitivity in resistant tumors. Despite these promising programs, Nuvectis remains deeply undervalued relative to peers. The company’s market cap sits around $150 million — a fraction of other precision oncology players at similar stages. Nuvalent (NASDAQ: NUVL), for example, trades north of $6 billion with programs focused on the same indication space. Summit Therapeutics (NASDAQ: SMMT), which also targets drug-resistant cancers, surged to nearly $15 billion in valuation earlier this year following a pivotal trial result. Nuvectis isn’t there yet — but if it delivers on either of its two clinical programs, it may not be far behind. Importantly, the company is financially stable. Nuvectis raised $15.5 million in early 2025, bringing its total cash reserves to nearly $30 million as of March. That provides runway into 2027, giving it ample time to reach key milestones without returning to the market for funding. It also means less dilution risk — a crucial factor for investors in early-stage biotech. This backdrop of strong insider ownership, solid financials, and high-impact drug development is what makes the Mosseri-Marlio buying spree so compelling. He’s not the only one with conviction either — CEO Ron Bentsur and other insiders continue to hold sizable stakes and have not sold a single share. Bentsur, notably, has a track record of taking biotech companies through FDA approval and delivering real value to shareholders. Year-to-date, NVCT is up significantly but it’s still relatively under the radar. That may not last long. With clinical data expected soon, strong internal alignment, and one of the most experienced insider buyers in the sector continuing to build his position, Nuvectis Pharma may be one of the few small-cap biotechs positioned for a breakout in the second half of 2025. - News Highlights from Nuvectis Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting - * Paid Advertisement Disclaimer & Disclosure: This content is not financial or investment advice, and the authors are not licensed brokers, dealers or advisors. This article was Published by the. Wall Street Wire™ platform and network, which is operated by Arx Advisory Ltd (the “Operators”). The Operators receive a monthly cash subscription fee from Nuvectis Pharma (NVCT) via bank transfer for services relating to promotional content and news distributions on various media and social channels. The Operators may received additional cash fees for monitoring, data or IR/advisory services on top of that. For specific details and full disclosures on the exact cash amounts paid for the Wall Street Wire subscription and the start date of such services, please refer to our full disclosure document: https://redditwire.com/terms Contact Details News Coverage media.globalmarkets@gmail.com

June 20, 2025 11:56 AM Eastern Daylight Time

With Fresh Funding and Strong Phase 3 Data, PolyPid Advances Towards FDA Approval

Global Markets News

PolyPid Ltd. (NASDAQ: PYPD) * announced Tuesday that it has secured $26.7 million through warrant exercises following its successful SHIELD II Phase 3 trial results. This funding milestone extends the company’s runway beyond the anticipated FDA approval of its breakthrough surgical infection prevention technology, D-PLEX₁₀₀. For savvy biotech investors seeking undervalued opportunities with near-term catalysts, PolyPid presents a compelling case study in market inefficiency and potential outsized returns. A David Taking On a $10 Billion Goliath Surgical site infections (SSIs) represent a massive burden on healthcare systems, costing hospitals tens of thousands of dollars per incident while significantly increasing patient mortality. The $10 billion SSI prevention market has long awaited innovation beyond traditional antibiotic approaches. Enter PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) platform, which delivers targeted antibiotics directly at surgical sites for a full 30 days—dramatically longer than conventional methods that typically provide only hours of protection. “D-PLEX₁₀₀ demonstrated a statistically significant reduction in surgical site infections and successfully met the study’s primary endpoint and all key secondary endpoints,” the company stated in its announcement of the Phase 3 SHIELD II trial results. Most impressively, in patients with large surgical incisions, earlier SHIELD I data showed a remarkable 54% reduction (p=0.0032) in the composite endpoint of infections, reinterventions, and mortality compared to standard of care alone. The more recent SHIELD II trial demonstrated an even more stunning 58% reduction in surgical site infections, dropping infection rates from 9.5% with standard care to just 3.8% when D-PLEX100 was added. Why This $36M Company Could Soon Command a Valuation in the Hundreds of Millions Despite delivering transformative clinical results, PolyPid currently trades around $3.53 per share (as of June 18, 2025), representing a market cap of approximately $36 million – a significant discount to comparable companies in the surgical and pain management sectors, many of which command valuations in the hundreds of millions to over $1 billion. This valuation disconnect creates a potential opportunity for investors ahead of multiple catalysts: 1. NDA Submission in Early 2026: The company expects to file its New Drug Application in early 2026, leveraging Fast Track and Breakthrough Therapy designations already granted by the FDA. 2. Medicare’s New Technology Add-On Payment Eligibility: D-PLEX₁₀₀ qualifies for this program, potentially providing up to 75% reimbursement during early commercialization years. 3. U.S. Partnership Discussions: Management noted during a recent call that there has been “a change in partnering interest following December’s interim analysis,” with large pharmaceutical and medical device companies representing logical partners. 4. Substantial Market Opportunity: With 12 million eligible surgeries annually in the U.S. alone and another 8 million in Europe, D-PLEX₁₀₀’s market potential is substantial. 5. European Partnership Already Secured: PolyPid has secured a European commercialization partnership with Advanz Pharma worth up to $115 million plus double-digit royalties. The newly secured $26.7 million adds to PolyPid’s existing capital resources. With this additional funding, the company has stated that its runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀. Beyond D-PLEX₁₀₀: Platform Technology Offers Additional Growth Potential While D-PLEX₁₀₀ drives immediate value creation, PolyPid’s broader PLEX platform provides significant growth opportunities beyond surgical infections. Their OncoPLEX program applies identical technology principles to deliver cancer therapeutics directly to tumor sites, potentially revolutionizing solid tumor treatment approaches. A recent collaboration with ImmunoGenesis validates the platform’s broader applications beyond surgical infections. According to recent analyst reports, Wall Street remains bullish on PolyPid. H.C. Wainwright recently raised their price target to $13 (from $11), while analysts from JMP Securities and Craig-Hallum have maintained Buy ratings. On June 5, 2025, Roth MKM initiated coverage with a Buy rating. The consensus among Wall Street professionals points to price targets ranging from $10-13, suggesting significant upside potential from current levels. The Bottom Line For investors seeking opportunities with clear catalysts, PolyPid represents a compelling combination of transformative clinical results, definitive regulatory pathway, and strong Wall Street support. With clinical risk substantially reduced following successful Phase 3 results and a regulatory submission timeline now established, the focus shifts to commercial execution and partnership value creation—potentially setting the stage for significant share price appreciation as these milestones materialize. The company’s notable discount to peers, extended cash runway, and multiple near-term value drivers make it an intriguing opportunity for biotech investors looking for undervalued assets with clear paths to value creation. Recent News Highlights from PolyPid PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints This article is syndicated from The Finance Herald. * Paid Advertisement Disclaimer & Disclosure: This article was Published by Wall Street Wire™. Wall Street Wire™ is owned and operated by Arx Advisory Ltd (the “Operator”). The Operator receives an ongoing monthly subscription fee of $5,000 cash via bank transfer (since May 1st, 2025 which is ongoing as of the date of publication) from PolyPid Ltd (PYPD) (IL0011326795) to produce and distribute this content and additional promotional content and news distributions on various media and social channels. The operator receives additional cash fees for non promotional data and consulting subscriptions from PolyPid. This content is not financial or investment advice, and the authors are not licensed brokers, dealers or advisors. Please refer to our full disclosure and disclaimer here: https://redditwire.com/terms. Contact Details Wall Street Wire media.globalmarkets@gmail.com

June 18, 2025 11:22 AM Eastern Daylight Time

News Release

LezDo TechMed Launches Seamless Medical Record Review Billing Through CaseDrive

LezDo TechMed

LezDo TechMed Launches Seamless Medical Record Review Billing Through CaseDrive New York, NY, United States, 18th Jun 2025 - LezDo TechMed, one of the leading medical record review outsourcing firms in the U.S, has officially launched its next-generation medical record review billing system through their product CaseDrive. With the launch of this one-of-a-kind tool, the company promises to deliver a seamless, transparent, and intelligent billing experience tailored for their clientele including IMEs, QMEs, law firms, insurance firms, and life care planners. Recognizing the persistent challenges surrounding the billing in outsourced medical record review services like hidden fees to confusing invoices and delayed payments, LezDo TechMed has introduced this cutting-edge solution designed to eliminate hassles and elevate client trust. At the focus of this innovation lies CaseDrive, the company’s AI-powered medical record platform that brings real-time billing visibility and automated invoicing for clients. “With this launch, we’re are happy to address one of the biggest pain points of our clients in the medical record review industry,” said a spokesperson for LezDo TechMed. “Our ultimate goal is to offer clients complete transparency, financial control, and ultimately peace of mind while trust us for their medical record review services like narrative summaries, medical chronologies, deposition summaries, APS summaries etc.” Advanced Features Now Live with CaseDrive Flexible Billing Cycles No more pressure on billing cycles! With CaseDrive, clients can choose a suitable billing cycle that aligns with their internal accounting process flow. Whether they prefer weekly, monthly or per case payments, LezDo TechMed ensures accurate, timely, and transparent invoicing with clearly itemized service breakdowns. Tailored Billing Packages From small firms to enterprise clients, the firm supports every client with tailored billing packages as per the criteria like case volume, turnaround time, and complexity, thereby maximizing cost efficiency without compromising service quality. Specialized Billing Summaries Billing summaries is another highlight that not only help clients understand what they’re paying for but also support in their audit preparation and financial documentation compliance with industry standards. CaseDrive is another promising launch by the firm, understanding the pain points the clients often face when it comes to outsourcing record review services. With this sophisticated innovation by LezDoTechMed, billing and payment in medical record review outsourcing had turned out to be a hassle-free journey for the clients. About LezDo TechMed LezDo TechMed is a renowned medical record review outsourcing company offering high-quality medical data analysis across the U.S. With its AI-powered medical data analysis and client-first approach, the firm stands out, leading innovation in medical record reviews and billing automation. Contact Details LezDo TechMed Robert Smith sales@lezdotechmed.com Company Website https://www.lezdotechmed.com/

June 18, 2025 10:50 AM Eastern Daylight Time

News Release

LezDo TechMed Launches Seamless Medical Record Review Billing Through CaseDrive

LezDo TechMed

LezDo TechMed, one of the leading medical record review outsourcing firms in the U.S, has officially launched its next-generation medical record review billing system through their product CaseDrive. With the launch of this one-of-a-kind tool, the company promises to deliver a seamless, transparent, and intelligent billing experience tailored for their clientele including IMEs, QMEs, law firms, insurance firms, and life care planners. Recognizing the persistent challenges surrounding the billing in outsourced medical record review services like hidden fees to confusing invoices and delayed payments, LezDo TechMed has introduced this cutting-edge solution designed to eliminate hassles and elevate client trust. At the focus of this innovation lies CaseDrive, the company’s AI-powered medical record platform that brings real-time billing visibility and automated invoicing for clients. “With this launch, we’re are happy to address one of the biggest pain points of our clients in the medical record review industry,” said a spokesperson for LezDo TechMed. “Our ultimate goal is to offer clients complete transparency, financial control, and ultimately peace of mind while trust us for their medical record review services like narrative summaries, medical chronologies, deposition summaries, APS summaries etc.” Advanced Features Now Live with CaseDrive Flexible Billing Cycles No more pressure on billing cycles! With CaseDrive, clients can choose a suitable billing cycle that aligns with their internal accounting process flow. Whether they prefer weekly, monthly or per case payments, LezDo TechMed ensures accurate, timely, and transparent invoicing with clearly itemized service breakdowns. Tailored Billing Packages From small firms to enterprise clients, the firm supports every client with tailored billing packages as per the criteria like case volume, turnaround time, and complexity, thereby maximizing cost efficiency without compromising service quality. Specialized Billing Summaries Billing summaries is another highlight that not only help clients understand what they’re paying for but also support in their audit preparation and financial documentation compliance with industry standards. CaseDrive is another promising launch by the firm, understanding the pain points the clients often face when it comes to outsourcing record review services. With this sophisticated innovation by LezDoTechMed, billing and payment in medical record review outsourcing had turned out to be a hassle-free journey for the clients. About LezDo TechMed LezDo TechMed is a renowned medical record review outsourcing company offering high-quality medical data analysis across the U.S. With its AI-powered medical data analysis and client-first approach, the firm stands out, leading innovation in medical record reviews and billing automation. Contact Details LezDo TechMed Robert Smith sales@lezdotechmed.com Company Website https://www.lezdotechmed.com/

June 18, 2025 10:30 AM Eastern Daylight Time

CURE ALZHEIMER’S FUND PRESENTS THE JEFFREY L. MORBY PRIZE FOR EXCEPTIONAL RESEARCH

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund, a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease (AD), has announced the recipients of the second annual Jeffrey L. Morby Prize. Senior author Andrew S. Yoo, Ph.D., and first author Zhao Sun, Ph.D., both of Washington University School of Medicine in St. Louis, were selected by their peers for their paper “ Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming,” published in Science in August 2024. The Morby Prize is named in honor of the late Co-Founder of Cure Alzheimer’s Fund, Jeffrey L. Morby, who inspired the nonprofit’s mission 20 years ago to fund research as a path to ending Alzheimer’s disease. Mr. Morby passed away in September 2023. Established in 2024, the Morby Prize will be awarded annually to the senior and first authors of a recent scientific publication that transforms the fundamental understanding of Alzheimer’s disease and opens new paths to translate scientific results into effective ways to prevent, diagnose or treat the disease. This year’s award included $200,000 for the senior author’s lab for Alzheimer’s disease-related research. “Honoring researchers whose work is determined by their peers as breakthrough thinking and having meaningful impact on the Alzheimer’s community is a fitting tribute to Jeff’s remarkable legacy of empowering scientists to pursue rigorous and innovative research,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “The many extraordinary CureAlz-funded projects that resulted in published papers in 2023 and 2024 made the competition for this award fierce, and the endorsement of this paper by their peers speaks to the importance of the work of Drs. Yoo and Sun and their co-authors.” The paper describes a groundbreaking method to study aged neurons in the lab without requiring a brain biopsy, enabling more accurate modeling of late-onset Alzheimer’s disease. By transforming skin cells from patients directly into neurons that reflect the aging process, scientists now can observe key disease features, such as amyloid beta plaque buildup, offering new insights into Alzheimer’s disease development and potential treatment approaches. “With the demonstration that direct neuronal reprogramming can model neuropathological features of late-onset Alzheimer’s disease, this method will enable us to dissect how aging, as the primary risk factor, contributes to neurodegeneration,” said Dr. Yoo. “Moreover, the generous support from the Jeffrey L. Morby Prize will further allow us to develop reprogramming approaches to generate different neuronal subtypes and investigate neuron-intrinsic aging mechanisms in the context of specific cell types. We are excited about the possibility of delineating the mechanisms by which different neuronal subtypes become vulnerable or resilient to AD with aging.” About The Yoo Lab Andrew S. Yoo, Ph.D., is a distinguished neuroscientist and professor in the Department of Developmental Biology at Washington University School of Medicine in St. Louis. His lab focuses on microRNAs as neurogenic genetic inputs and reprogramming effectors to generate human neurons by directly reprogramming non-neural somatic cells. Using this approach, his team investigates how aging in human neurons contributes to the adult- and late-onset of neurodegeneration employing neurons derived from individuals with various neurodegenerative disorders. About Cure Alzheimer's Fund Cure Alzheimer’s Fund is a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided 971 grants to more than 300 of the world’s leading researchers and contributed more than $232 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has achieved a 100% perfect score and a Four-Star rating for 13 consecutive years from Charity Navigator. Cure Alzheimer’s Fund also received a Platinum Seal of Transparency from Candid, formerly known as GuideStar. Our Board of Directors, Trustees and a core group of other donors direct their donations to our overhead expenses so that 100% of general donations go to our research program. For more information, visit CureAlz.org. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org Company Website http://curealz.org

June 18, 2025 05:25 AM Eastern Daylight Time

1 2 3 4 5 ... 316